INTERNATIONAL JOURNAL OF ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-06-09 ms7000000100090778

偏重的研究方向：肿瘤学
经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。
这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。

42 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-08-04 归浆

请问生信友好吗

56 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-09-01 ms8000000598680773

偏重的研究方向：肿瘤
经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个

50 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-10-27 Chaiii

请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知

52 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2021-07-01 卢芷菡

审稿速度:2.0 | 投稿命中率:75.0
经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收

105 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-10-06 ms4000000323641493

under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。

50 0

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-08-10 ms6000000300077126

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;基础研究
经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。

41 0

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2020-02-27 qyqx1020153528@163.com

一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了

164 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-02-19 ms5000001945010335

17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊

43 0

[GetPortalCommentsPageByObjectIdResponse(id=1225411, encodeId=c00b1225411d4, content=偏重的研究方向：肿瘤学 经验分享：5月28日投稿，6月8日改好格式，6月9日发来了转投信，转投oncology reports。因为不想再折腾了，就转投了。研究生期间第一篇sci，希望能中吧。 这个杂志文字和图片格式要求特别多，而且对图片清晰度有很高要求。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=469b5577389, createdName=ms7000000100090778, createdTime=Thu Jun 09 12:02:51 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236583, encodeId=31fd123658393, content=请问生信友好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58bd5308246, createdName=归浆, createdTime=Thu Aug 04 14:53:38 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242375, encodeId=2cf812423e5d3, content=偏重的研究方向：肿瘤 经验分享：非常快，一个月结束外审，一个礼拜小修，过几天就录用了。赞一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=ms8000000598680773, createdTime=Thu Sep 01 01:28:27 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096374, encodeId=d90f20963e4a5, content=请问Under review是编辑在审还是送外审了？才几天，没收到改格式的通知或者其他通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/3a9c7ef3dd6048b8b686127b5ee0de32/143a4c51a73744e8be200915e0697a2d.jpg, createdBy=8ae95417517, createdName=Chaiii, createdTime=Thu Oct 27 02:41:57 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978710, encodeId=9a569e871034, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：2020年4.28提交 5.6通过内部审核后送审 6.26大修，要求不超过45天返修 7.21修回 8.1接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dd45247744, createdName=卢芷菡, createdTime=Thu Jul 01 19:50:34 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092100, encodeId=b1a420921008d, content=under review一个月后建议转投oncology reports。没有任何审稿意见。真耽误事儿啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=12fb5417689, createdName=ms4000000323641493, createdTime=Thu Oct 06 17:39:55 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237806, encodeId=82ad123e806c5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;基础研究 经验分享：4.1投稿；5.16一审，大修，45天内修回；6.1修回；6.30接收；7.20 final proof；7.28 汇款到账。总的来说，审稿人意见比较中肯，两位审稿人都有要求补实验，不过由于时间只补了一个。编辑对图片以及文章的格式，图注等一些细节十分在意，对于文章的创新性要求并没有太高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8dd5698708, createdName=ms6000000300077126, createdTime=Wed Aug 10 12:44:22 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585471, encodeId=41be5854e1c5, content=一审两个月小修但编辑要求润色顺便提到他们可以提供润色然后我自己找了家润色公司返修回去两周编辑直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/R29thWnr3VaNo7tZMZ8iaFZeFJxdMVcsbTKAOv6LJLxic5GDlE54icW5JJPO98xbML4vrwrgFADf3we9GtqEzoWPQ/132, createdBy=28cd2140928, createdName=qyqx1020153528@163.com, createdTime=Thu Feb 27 16:39:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195103, encodeId=684411951039d, content=17号投，18号und er review，然后凌晨4点拒了，建议转投别的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sat Feb 19 16:04:55 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196331, encodeId=afdc11963317d, content=2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f05713061, createdName=ms8000000295828130, createdTime=Wed Feb 23 09:49:17 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-02-23 ms8000000295828130

2月21号投稿，2月22号under review, 23号凌晨4点拒稿建议转投旗下的Oncology letters. 转投期刊2020年中级预警，遂放弃转投其他期刊。

43 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务